NWBO — Northwest Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $443.51m
- $519.52m
- $1.38m
Annual income statement for Northwest Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.29 | 1 | 1.68 | 1.93 | 1.38 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 89.5 | 53.9 | 71.6 | 62.8 | 82.3 |
| Operating Profit | -88.2 | -52.9 | -69.9 | -60.9 | -80.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -530 | 179 | -105 | -62.6 | -83.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -530 | 179 | -105 | -62.6 | -83.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -530 | 179 | -105 | -62.6 | -83.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -530 | 179 | -105 | -64.4 | -85.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.728 | 0.205 | -0.101 | -0.053 | -0.057 |